Compare Aventis Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs NATCO PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA NATCO PHARMA SANOFI INDIA/
NATCO PHARMA
 
P/E (TTM) x 42.0 35.0 119.9% View Chart
P/BV x 8.5 5.0 171.7% View Chart
Dividend Yield % 1.0 0.7 150.4%  

Financials

 SANOFI INDIA   NATCO PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
NATCO PHARMA
Mar-19
SANOFI INDIA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6,840849 805.7%   
Low Rs4,630557 831.2%   
Sales per share (Unadj.) Rs1,203.1573.8 209.7%  
Earnings per share (Unadj.) Rs165.3176.0 93.9%  
Cash flow per share (Unadj.) Rs209.9198.2 105.9%  
Dividends per share (Unadj.) Rs84.006.25 1,344.0%  
Dividend yield (eoy) %1.50.9 164.7%  
Book value per share (Unadj.) Rs963.6842.7 114.3%  
Shares outstanding (eoy) m23.0336.50 63.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.81.2 389.1%   
Avg P/E ratio x34.74.0 868.8%  
P/CF ratio (eoy) x27.33.5 770.5%  
Price / Book Value ratio x6.00.8 713.5%  
Dividend payout %50.83.6 1,431.3%   
Avg Mkt Cap Rs m132,07825,660 514.7%   
No. of employees `0003.35.0 66.6%   
Total wages/salary Rs m4,0683,559 114.3%   
Avg. sales/employee Rs Th8,393.84,225.3 198.7%   
Avg. wages/employee Rs Th1,232.4718.0 171.6%   
Avg. net profit/employee Rs Th1,153.01,295.9 89.0%   
INCOME DATA
Net Sales Rs m27,70820,945 132.3%  
Other income Rs m8971,302 68.9%   
Total revenues Rs m28,60522,247 128.6%   
Gross profit Rs m6,2357,948 78.4%  
Depreciation Rs m1,027810 126.8%   
Interest Rs m7193 3.6%   
Profit before tax Rs m6,0988,247 73.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2921,823 125.7%   
Profit after tax Rs m3,8066,424 59.2%  
Gross profit margin %22.537.9 59.3%  
Effective tax rate %37.622.1 170.0%   
Net profit margin %13.730.7 44.8%  
BALANCE SHEET DATA
Current assets Rs m15,92223,472 67.8%   
Current liabilities Rs m6,2357,287 85.6%   
Net working cap to sales %35.077.3 45.2%  
Current ratio x2.63.2 79.3%  
Inventory Days Days6492 69.0%  
Debtors Days Days2188 23.7%  
Net fixed assets Rs m7,53918,648 40.4%   
Share capital Rs m230365 63.0%   
"Free" reserves Rs m21,96234,525 63.6%   
Net worth Rs m22,19230,760 72.1%   
Long term debt Rs m00-   
Total assets Rs m29,83943,031 69.3%  
Interest coverage x872.143.7 1,994.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 190.8%   
Return on assets %12.815.4 83.1%  
Return on equity %17.220.9 82.1%  
Return on capital %27.527.4 100.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58711,536 65.8%   
Fx outflow Rs m7,1452,939 243.1%   
Net fx Rs m4428,597 5.1%   
CASH FLOW
From Operations Rs m3,7396,688 55.9%  
From Investments Rs m-731-6,122 11.9%  
From Financial Activity Rs m-1,972-509 387.4%  
Net Cashflow Rs m1,03666 1,569.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 60.4 1.5 4,108.8%  
Indian inst/Mut Fund % 14.4 7.8 183.7%  
FIIs % 14.6 16.6 87.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 26.0 40.4%  
Shareholders   15,184 25,395 59.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FDC.  UNICHEM LAB  PROCTER & GAMBLE HEALTH  ELDER PHARMA  ALEMBIC  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 110 Points Lower; Smallcap & Midcap Stocks Outperform(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower, ahead of Q2 GDP data.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Shine More than Gold After Diwali(Profit Hunter)

Nov 17, 2020

If the markets become volatile over the next few months, do this.

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

How to Build the Best Trading System(Fast Profits Daily)

Nov 20, 2020

In this video, I'll show you how to make the best trading system.

An Eraser and Some Pencils(The Honest Truth)

Nov 17, 2020

Ajit Dayal on the road ahead for the world after covid.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 27, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS